NLS Pharmaceutics and Kadimastem granted patent in Hong Kong for diabetes

NLS Pharmaceutics (NLSP)’ merger partner Kadimastem has been granted a patent by the Hong Kong Intellectual Property Department covering Kadimastem’s proprietary cell selection and enrichment technology used in the development of IsletRx, a stem cell-derived therapy candidate intended to treat-and potentially cure-insulin-dependent diabetes. According to Kadimastem, the Hong Kong patent adds to previously granted patents in Europe, the United States and India, further strengthening the global protection around IsletRx. The patented process enables the selection and enrichment of highly functional islet cells from differentiated cell populations to help maximize therapeutic effect.